LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Embecta Corp

Închisă

SectorSănătate

11.72 -0.59

Rezumat

Modificarea prețului

24h

Curent

Minim

11.67

Maxim

12.08

Indicatori cheie

By Trading Economics

Venit

-19M

26M

Vânzări

-32M

264M

P/E

Medie Sector

7.364

76.798

Randament dividend

5.08

Marjă de profit

10

Angajați

1,850

EBITDA

-40M

71M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+112.22% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

5.08%

2.37%

Statistici piață

By TradingEconomics

Capitalizare de piață

-96M

698M

Deschiderea anterioară

12.31

Închiderea anterioară

11.72

Sentimentul știrilor

By Acuity

56%

44%

312 / 374 Clasament în Healthcare

Embecta Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 dec. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec. 2025, 23:51 UTC

Câștiguri

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec. 2025, 23:39 UTC

Principalele dinamici ale pieței

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec. 2025, 21:40 UTC

Câștiguri

Nike Sales Tick Up, But China Weakness Persists

18 dec. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec. 2025, 23:37 UTC

Market Talk
Câștiguri

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec. 2025, 22:58 UTC

Achiziții, Fuziuni, Preluări

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec. 2025, 22:56 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec. 2025, 22:55 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:59 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 dec. 2025, 21:35 UTC

Câștiguri

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec. 2025, 21:31 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev Down 17% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q EPS 53c >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Apparel Rev $3.91B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Equipment Rev $550M >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q N Amer Rev $5.63B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Footwear Rev $7.66B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev $1.42B >NKE

Comparație

Modificare preț

Embecta Corp Așteptări

Obiectiv de preț

By TipRanks

112.22% sus

Prognoză pe 12 luni

Medie 25 USD  112.22%

Maxim 25 USD

Minim 25 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEmbecta Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

312 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat